SCHEMBL30097062

SCHEMBL30097062

CC(C)(C)OC(=O)NCc1cc2cc(Br)ccc2cn1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4A O75164 1/20 0.42
DYRK1A Q13627 2/20 0.40
GSK3B P49841 1/20 0.40
AAK1 Q2M2I8 6/20 0.40
L3MBTL1 Q9Y468 1/20 0.39
EGFR P00533 1/20 0.39
RAF1 P04049 1/20 0.39
KDR P35968 1/20 0.39
MAP2K2 P36507 1/20 0.39
MAP2K1 Q02750 1/20 0.39
AURKB Q96GD4 1/20 0.39
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA9 Q16790 1/20 0.38
HDAC1 Q13547 2/20 0.37
HDAC2 Q92769 2/20 0.37
IGF1R P08069 1/20 0.37
PDPK1 O15530 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26143885 1.00 KDM4A (0.42) KDM4ADYRK1AGSK3BAAK1L3MBTL1
SCHEMBL31401432 0.85 GAA (0.42) KDM4ADYRK1AGSK3BL3MBTL1
SCHEMBL3633138 0.85 KDM4A (0.54) KDM4ADYRK1AL3MBTL1CA12CA1
SCHEMBL26143902 0.83 AAK1 (0.40) KDM4ADYRK1AAAK1L3MBTL1EGFR
SCHEMBL13707719 0.82 L3MBTL1 (0.43) KDM4AAAK1L3MBTL1CA12CA1
SCHEMBL29990381 0.82 L3MBTL1 (0.43) KDM4AAAK1L3MBTL1CA12CA1
SCHEMBL26143921 0.81 NAMPT (0.45) KDM4ADYRK1AL3MBTL1CA12CA1
SCHEMBL30097039 0.81 NAMPT (0.45) KDM4ADYRK1AL3MBTL1CA12CA1
SCHEMBL12056510 0.81 GSK3B (0.38) DYRK1AGSK3BAAK1L3MBTL1EGFR
SCHEMBL17309330 0.81 KDM4A (0.43) KDM4AAAK1L3MBTL1EGFRRAF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12441726-B2 Compounds and uses thereof FOGHORN THERAPEUTICS, INC. (US) 2025-10-14 US disclosed
EP-4522280-A1 COMPOUNDS AND USES THEREOF Foghorn Therapeutics Inc. (US) 2025-03-19 EP disclosed
WO-2023220219-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2023-11-16 WO disclosed
US-20230145003-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-11 US disclosed
EP-4096667-A1 COMPOUNDS AND USES THEREOF Foghorn Therapeutics Inc. (US) 2022-12-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12441726-B2 Compounds and uses thereof VHL, CLN6, TFEB KDM4A 2166/4885DYRK1A 4550/4885GSK3B 3110/4885
US-20230145003-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB KDM4A 2166/4885DYRK1A 4550/4885GSK3B 3110/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.